Skip to Main Content

LIVEBETTER (a trial comparing the effectiveness and tolerability of medications in older adults with stable angina and multiple chronic conditions)

  • Study HIC#:2000034470
  • Last Updated:05/03/2024

The purpose of the LIVEBETTER study is to learn how older patients with heart disease tolerate the two primary medication groups that are currently available to treat symptoms of angina. The study will compare how Beta-Blocker and Calcium Channel Blocker medications work to improve patients’ symptoms and overall quality of life. People who participate will be randomly assigned to one of these two groups of medications, and they will be followed for one year with interviews and a short walk assessment.

Contact information:

Michael G. Nanna, MD, MHS, FSCAI, FACC

Section of Cardiovascular Medicine

Yale School of Medicine

Email: livebetter-trial@yale.edu

Toll-Free: (888) 683-0865 – please state you are calling about the LIVEBETTER heart study.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Michael G. Nanna, MD, MHS, FSCAI, FACC

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    The purpose of the LIVEBETTER study is to learn how older patients with heart disease tolerate the two primary medication groups that are currently available to treat symptoms of angina. The study will compare how Beta-Blocker and Calcium Channel Blocker medications work to improve patients’ symptoms and overall quality of life. People who participate will be randomly assigned to one of these two groups of medications, and they will be followed for one year with interviews and a short walk assessment.


    Eligibility Criteria

    Age: 70 years and older (65 years and older for Black/African American and Hispanic participants)

    Gender: Both

    Health History: Heart disease with symptoms; NOT currently taking a Beta-Blocker or Calcium Channel Blocker medication

    Principal Investigator

    Sub-Investigators

    For more information about this study, including how to volunteer, contact:

    Michael G. Nanna, MD, MHS, FSCAI, FACC